PEPTIDE RESEARCH TOPIC

AOD-9604 Research Peptide

Explore AOD-9604 research, growth hormone-fragment identity, metabolic and animal studies, evidence limitations, and regulatory safety information.

TOPIC OVERVIEW

About AOD-9604

Identity and names

AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone. It is not equivalent to full-length somatropin.

Compound type

It is a short synthetic peptide fragment with an added N-terminal tyrosine. Sequence identity should be verified rather than inferred from HGH-fragment marketing.

Mechanism

Research examines lipid metabolism and other model-specific effects. It should not be described as having all of growth hormone's actions.

Research focus and evidence

Published experiments include obese-mouse metabolic studies and a rabbit osteoarthritis model. These endpoints do not establish human weight-loss or joint-repair benefits.

Regulatory status and limits

FDA discusses characterization, immunogenicity, limited safety information, and reported adverse events with uncertain causality. This is not an approved weight-management medicine.

Topics covered
  • growth hormone fragment identity
  • lipid metabolism models
  • joint research
  • safety and evidence gaps
Common names and related terms: AOD-9604, AOD9604
RESEARCH SUMMARY

What Is AOD-9604?

LAST VERIFIEDOctober 7, 2026

An obese-mouse study evaluated AOD-9604 and growth hormone in lipid-metabolism experiments. Animal metabolic outcomes cannot establish a human weight-loss effect. AOD-9604 mouse metabolic study

FDA identifies safety and characterization concerns for compounded AOD-9604 and notes serious adverse-event reports with unclear causality. Lack of proven causality does not establish safety. FDA, AOD-9604 safety information

EVIDENCE PROFILE

AOD-9604 Research Evidence

A concise view of registered clinical research, PubMed-indexed literature, evidence stage, and important limitations.

LAST VERIFIEDOctober 7, 2026
Registered records0
Active studies0
Completed studies0
PubMed records22
Compound typeIt is a short synthetic peptide fragment with an added N-terminal tyrosine. Sequence identity should be verified rather than inferred from HGH-fragment marketing.
AliasesAOD-9604, AOD9604
Evidence stagePublished experiments include obese-mouse metabolic studies and a rabbit osteoarthritis model. These endpoints do not establish human weight-loss or joint-repair benefits.
U.S. regulatory contextFDA discusses characterization, immunogenicity, limited safety information, and reported adverse events with uncertain causality. This is not an approved weight-management medicine.
CLINICAL REGISTRY

Selected registered research

No matching intervention record was found in ClinicalTrials.gov during this verification. This does not mean that no research exists.

INDEXED LITERATURE

Selected PubMed records

PMID 117132132001 Dec · Endocrinology

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

PMID 414902002026 Jan 1 · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

PMID 151342862004 Apr · Current opinion in investigational drugs (London, England : 2000)

AOD-9604 Metabolic.

How to interpret this profile

Registry and publication counts describe discoverable records, not proof of effectiveness or safety. Study design, compound identity, population, endpoints, and regulatory context must be reviewed individually.

Primary sources: ClinicalTrials.gov (defined search) · PubMed (defined query)Checked October 7, 2026. Counts include interventional registry records with an explicit matching intervention name or alias; broad search results, biomarker-only observations, and unrelated compounds are excluded. Active includes recruiting, not yet recruiting, active not recruiting, and enrolling by invitation. PubMed is the linked title/abstract query count, not a number of clinical trials or a measure of evidence quality.

Displayed records are selected for relevance and recency; the page does not reproduce the complete source databases.

START HERE

Essential AOD-9604 guides

AOD-9604 KNOWLEDGE ARTICLESPage 1 of 11
01
KNOWLEDGE ARTICLE

AOD-9604 5mg Dosage: Research Protocol Guide

AOD-9604 5 mg vial calculations: compare final volumes, mg/mL, and mcg conversions while separating concentration arithmetic from unestablished human dosing.

↗
02
KNOWLEDGE ARTICLE

AOD 9604 Acetic Acid: Reconstitution Guide

AOD 9604 acetic acid is used to dissolve this research peptide. Learn how reconstitution works, solubility tips, storage, and why acetic acid is needed.

↗
03
KNOWLEDGE ARTICLE

Dosage for AOD 9604: Research Dosing Guide

Dosage for AOD 9604: oral study amounts, unsupported injection ranges, hypothetical 5 mg vial calculations, and limits of sex-specific and timing claims.

↗
09
KNOWLEDGE ARTICLE

How to Use AOD 9604: Peptide Dosing and Safety

How to use AOD-9604: distinguish laboratory handling from human treatment, compare study routes, and assess the evidence behind injection instructions.

↗
12
KNOWLEDGE ARTICLE

AOD 9604 Dosage for Men: Research Dosing Guide

AOD-9604 dosage for men: distinguish oral trial arms from unvalidated injection amounts, beginner schedules, timing claims, and concentration arithmetic.

↗
13
KNOWLEDGE ARTICLE

How Much Does AOD 9604 Cost? Vial vs. Clinic Prices

How much does AOD 9604 cost? Research vials run $30–$150, troches $150–$400, and clinic peptide programs $200–$600 per month. Prices vary by dose and vendor.

↗
14
KNOWLEDGE ARTICLE

AOD 9604 and CJC-1295 Stack: What to Know

Wondering whether an aod 9604 and cjc-1295 stack makes sense? Compare mechanisms, evidence, and safety, and see how both differ from GLP-1 drugs.

↗
15
KNOWLEDGE ARTICLE

AOD 9604 Peptide Dose: Research Dosing Guide

AOD-9604 peptide dose: distinguish oral study amounts from injection claims, and learn why laboratory concentration calculations do not establish a human dose.

↗
16
KNOWLEDGE ARTICLE

AOD-9604 Gelling Up: Causes & Fixes

AOD-9604 gelling up is a common reconstitution problem. Learn why the peptide clumps, how to prevent it, and proper handling for research use.

↗
17
KNOWLEDGE ARTICLE

AOD 9604 Nasal Spray Dosage: A Practical Guide

AOD 9604 nasal spray dosage usually falls between 300 and 600 mcg per day, split into one or two doses. Learn protocols, dosing, timing, and safety.

↗
18
KNOWLEDGE ARTICLE

Lipotropin HCL-AOD 9604: What Research Shows

Lipotropin HCL-AOD 9604 is a research peptide studied for fat metabolism. Learn how it works, typical dosing research, side effects, and safety.

↗